Authorization

South Rampart Pharma Announces Late-Breaking Presentation at IASP 2022 World Congress on Pain

NEW ORLEANS, Aug. 25, 2022 /PRNewswire/ -- South Rampart Pharma ("South Rampart" or the "Company"), a clinical-stage life science company advancing innovative medications for the treatment of pain and fever, today announced that the Company will present a late-breaking abstract at the International Association for the Study of Pain (IASP) 2022 World Congress on Pain, which will take place on September 20-23, 2022, in Toronto, Canada.
South Rampart Pharma Announces Late-Breaking Presentation at IASP 2022 World Congress on Pain
The late-breaking presentation, entitled "Novel Non-Opioid Analgesic for Acute and Chronic Pain: From Discovery to Phase 1 Trial," will chronicle the invention and development of SRP-001 (previously known as SRP-3D (DA)). Central to SRP-001's therapeutic differentiation, this non-opioid investigational pain medication exhibits comparable, if not better, efficacy as similar approved drugs but notably does not exhibit their liver or kidney toxicity. South Rampart's CEO and Co-founder, Hernan Bazan, MD, FACS, will deliver the presentation."I'm delighted to have this opportunity to showcase the groundbreaking work we've done with SRP-001," commented Dr. Bazan. "Liver toxicity associated with acetaminophen is the leading cause of acute liver failure in the United States. As a practicing vascular surgeon, I have routinely informed my practices in the ER and beyond." Dr. Bazan continued, "During the rationale design of SRP-001, we specifically set out to engineer a next-generation analgesic that both maintains the integrity of the clinically validated mechanism of action as acetaminophen while simultaneously muting the biological activity that leads to liver toxicity, thereby widening the therapeutic index by an order of magnitude. As such, we believe SRP-001 represents a unique opportunity to potentially transform the treatment of pain a?? replacing existing treatments a?? and deliver everyday relief on a significant scale." The World Congress on Pain is the largest global gathering of pain professionals. This event brings together more than 7,000 scientists, clinicians, and healthcare providers worldwide and across the pain discipline.A Differentiated Approach to Pain Management Innovation South Rampart Pharma's lead program, SRP-001, is a novel acetaminophen analog with a unique mechanism of action for its lack of liver toxicity present in acetaminophen. In development to treat acute and other forms of pain, evidence to date demonstrates that SRP-001 offers a compelling safety profile over currently available pain medications, including:
See also:
Leave a comment
News
  • Latest
  • Read
  • Commented
Calendar Content
«    Февраль 2023    »
ПнВтСрЧтПтСбВс
 12345
6789101112
13141516171819
20212223242526
2728